Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1985-03-14
1987-03-24
Jiles, Henry R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514228, 514234, 514236, 514252, 514253, 514316, 514318, 514338, 514343, 514788, 514947, 546187, 546194, 546270, 546272, 546281, 544121, 544130, 544131, 544357, 544364, C07D40112, C07D41314, C07D40114, A61K 31455
Patent
active
046525734
ABSTRACT:
Compounds having calcium channel antagonist activity of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each independently amino, trifluoromethyl, pentafluoroethyl, alkoxy, lower alkenyl, or lower alkynyl or branched or unbranched lower alkyl, which is unsubstituted or is substituted with cyano, hydroxy, acyloxy, hydrazino, lower alkyl amino, or di(lower alkyl)-amino or 5 or 6 membered saturated nitrogen-containing heterocyclic-1-yl, which is unsubstituted or is substituted with oxo, hydroxy, alkyl, and hydroxy (lower alkyl) R.sub.3 is straight- or branched-chain C.sub.1 to C.sub.12 alkyl, alkenyl, alkynyl, or cycloalkyl, and is either unsubstituted or substituted with hydroxy, acyloxy, cyano, di(lower alkyl) amino 5- or 6-membered saturated nitrogen-containing heterocyclic-1-yl or R.sub.3 is --A-R.sub.4, A is a straight- or branched-chain hydrocarbon moiety containing from 2 to 12 carbon atoms and from 0 to 2 double bonds, R.sub.4 is selected from the group consisting of: ##STR2## R.sub.5 is hydrogen, nitro, cyano, azido, amino, trifluoromethyl, alkylamino, dialkylamino, halo, carboxyl, carbalkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, acylamino, carboxamido, sulfonamide, and SO.sub.m -(lower)alkyl where m is 0, 1, or 2 and R.sub.6 is aryl or heteroaryl or a pharmaceutically-acceptable salt thereof are disclosed. Also disclosed is a method of treating hypertension and other disorders by administering an effective amount of a compound of the present invention.
REFERENCES:
patent: 3441648 (1969-04-01), Loev et al.
patent: 3488359 (1970-06-01), Bossert et al.
patent: 3511847 (1970-05-01), Loev et al.
patent: 3644627 (1972-02-01), Bossert et al.
patent: 3691177 (1972-09-01), Bossert et al.
patent: 4145432 (1979-03-01), Sato
patent: 4284634 (1981-08-01), Sato
patent: 4307103 (1981-12-01), Sato et al.
patent: 4338322 (1982-07-01), Sato
patent: 4370334 (1983-01-01), Sato
patent: 4430333 (1984-02-01), Campbell et al.
patent: 4450165 (1984-05-01), Araki et al.
patent: 4532248 (1985-07-01), Franckowiak et al.
R. A. Janis, J. Triggle, New Developments in Ca.sup.2+ Channel Antagonists, Journal of Medicinal Chemistry, 775-785.
H. Meyer, S. Kazda, P. Bellemann, Calcium Antagonists--New Opportunities, Annual Reports in Medicinal Chemistry, 79-88.
Rogg, H. et al., "In Vitro Comparative Studies of the Calcium-entry Activators", Journal of Cardiovascular Pharmacology.
Bossert et al., "4-Aryl Dihydropyridines", Angew. Chem. Int. Ed. Engl. 20 (1981), pp. 762-769.
Schramm et al., "Novel Dihydropyridines with Positive Inotropic Action", Nature, vol. 303 (Jun. 9, 1983), pp. 535-537.
Minaskanian Gevork
Rajadhyaksha Vithal J.
Baran Robert J.
Bjorkman Dale A.
Jiles Henry R.
Nelson Research & Development Co.
LandOfFree
Calcium antagonist N-hetero ester 1,4-dihydropyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium antagonist N-hetero ester 1,4-dihydropyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium antagonist N-hetero ester 1,4-dihydropyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1354179